domenica, 29 novembre 2020
Medinews
18 Maggio 2018

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between … (leggi tutto)

Cabozantinib costituisce un agente terapeutico fattibile ed attivo nel carcinoma del rene avanzato anche in una popolazione eterogenea e non selezionata. In particolare il dato di safety è confortante a supporto dell’utilizzo di cabozantinib nella pratica clinica quotidiana.
TORNA INDIETRO